DROR
Dror Ortho-Design, Inc.0.0110
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
10.53MP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
8-K
Closes $200K debenture deal
Dror Ortho-Design closed a $200,000 private placement of 0% interest debentures due April 27, 2026, on February 26, 2026. They convert automatically into common stock at the public offering price if one occurs before maturity, while holders get warrants tied to any future public offering—150% if debentures remain outstanding. Short-term bridge financing. Conversion hinges on public offering.
10-K
FY2025 results
Dror Ortho-Design posted FY2025 net loss of $2.5M, improved from $5.8M in FY2024, yet no revenue as development-stage orthodontic innovator. Losses narrowed on 47% R&D cut to $816K and 98% drop in share-based comp to $39K, while G&A held steady; cash burn eased to $2.1M from $2.7M. Bridge loans supplied $1.75M, leaving $228K cash amid $2.7M working capital deficit—going concern flagged. ZSmile Platform snagged FDA clearance February 2026. No dividends, buybacks, or capex spikes. Israeli operations risk quarterly momentum from regional conflicts.
8-K
Secures $250K debentures
Dror Ortho-Design secured $250,000 via private placement of 0% interest debentures due February 28, 2026, consummated December 30, 2025. These convert automatically into common stock upon a public offering at the offering price, while warrants—up to 150% of debenture shares—issue concurrently, exercisable five years at that price. Short-term bridge funds dilution hinges on public offering timing.
8-K
Secures $200K debentures
Dror Ortho-Design secured $200,000 via private placement of 0% interest debentures maturing February 2, 2026, closing December 2, 2025. They auto-convert to common stock upon a public offering at its price; warrants kick in post-IPO at 100-150% coverage. Short-term bridge funds liquidity. Holders capped at 9.99% ownership.
10-Q
Q3 FY2025 results
Dror Ortho-Design narrowed its Q3 operating loss to $469,880 from $1.3M a year ago, thanks to R&D expenses dropping 66% y/y to $151K on lighter software work, while G&A held steady near $318K. Cash burn eased to $1.4M YTD (vs $2.2M last year), funded by $1.1M in convertible notes now at $802K net with Dec 2025 maturities; quarter-end cash sits at $240K. No revenue yet as the orthodontic platform awaits FDA clearance. Operations remain Israel-based. Going concern doubts linger.
ALGN
Align Technology, Inc.
162.89+0.16
AUR
Aurora Innovation, Inc.
4.12-0.06
HYDTF
Hydreight Technologies Inc
3.10-0.06
MGRM
Monogram Technologies Inc.
6.00+0.00
MRM
MEDIROM Healthcare Technologies
2.10+0.01
ODYS
Odysight.ai Inc.
3.10+0.04
VVOS
Vivos Therapeutics, Inc.
2.02+0.00
WYFI
WhiteFiber, Inc.
15.08-0.13
ZIMV
ZimVie Inc.
18.99+0.00
ZOOZ
ZOOZ Strategy Ltd.
0.42+0.00